Who makes ARQ-154 Foam 0.3%?

ARQ-154 Foam 0.3% is developed by Arcutis Biotherapeutics, Inc..

What development phase is ARQ-154 Foam 0.3% in?

ARQ-154 Foam 0.3% is in Phase 1.

Last reviewed 2026-04-23 · How we verify

ARQ-154 Foam 0.3%

Arcutis Biotherapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	ARQ-154 Foam 0.3%
Sponsor	Arcutis Biotherapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis (PHASE1)
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) (PHASE3)
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis (PHASE2)
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) (PHASE3)
Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis (PHASE2)
Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ARQ-154 Foam 0.3% CI brief — competitive landscape report
ARQ-154 Foam 0.3% updates RSS · CI watch RSS
Arcutis Biotherapeutics, Inc. portfolio CI